Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01302067 · ClinicalTrials.gov registry record · Phase 4
A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 2,012
- Enrollment target
NCT01302067 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 2,012 participants.
The verdict
NCT01302067, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2,012 participants
- Enrollment target
Study Summary
This study is designed to confirm if 8mg of fesoterodine is more effective in reducing overactive bladder symptoms than 4mg of fesoterodine. In addition the study is designed to assess if the higher dose reduces the overall effect of overactive bladder on the subject's daily life more than the lower dose. The study also assesses the side effects and safety of the two doses.
Interventions
- DRUG Placebo
- DRUG Fesoterodine 8mg
- DRUG Fesoterodine 4mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,012 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01302067
The ClinicalTrials.gov registry entry for NCT01302067 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 2,012 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01302067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01302067 about?
NCT01302067 is a clinical study titled "A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine". This study is designed to confirm if 8mg of fesoterodine is more effective in reducing overactive bladder symptoms than 4mg of fesoterodine. In addition the study is designed to assess if the higher dose reduces the overall effect of overactive bladder on the subject's daily life more than the lower...
What is the current status of trial NCT01302067?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2,012 participants. The study started on 2011-05. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01302067?
The interventions under investigation include: Placebo (DRUG), Fesoterodine 8mg (DRUG), Fesoterodine 4mg (DRUG).
Who is sponsoring clinical trial NCT01302067?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.